RE:Target price $0.80Yeah and that's just the current core business with some pretty conservative growth baked in. Add in Kinlytic for just the current indication and geography that was partnered and that's another buck. That partnership will be expanded for the current indication to other geographies and for new indications and geographies in due course, but not until the new drug manufacturing is approved, which is extremely low risk. If I gave my thoughts on what the new indications and geographies could be worth probably only a very few here would even know what I was talking about and the rest would laugh me out of the room, but it will come.